EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Protein‐Like Polymers Targeting Keap1/Nrf2 as Therapeutics for Myocardial Infarction

Joshua M Mesfin iD, Kendal P Carrow iD, Alexander Chen, Madeline P Hopps iD, JoJo J Holm, Quincy P Lyons, Michael B Nguyen, Jervaughn D Hunter, Assa Magassa iD, Elyse G Wong, Kate Reimold, Sriya N Paleti und 6 weitere

Advanced Materials · 2025-07 · 37 (27)

DOI: 10.1002/adma.202417885 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 25.04.2025. Verfasst von Joshua M Mesfin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Shu Chien-Gene Lay Department of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California San Diego, La Jolla, CA, 9203…. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Kelch-Like ECH-Associated Protein 1, Myocardial Infarction, Polymers. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Lurie Cancer Center, NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myocardial infarction (MI) results in oxidative stress to the myocardium and frequently leads to heart failure (HF). There is an unmet clinical need to develop therapeutics that address the inflammatory stress response and prevent negative left ventricular remodeling. Here, the Keap1/Nrf2 protein–protein interaction is specifically targeted, as Nrf2 activation is known to mitigate the inflammatory response following MI. This is achieved using a Nrf2‐mimetic protein‐like polymer (PLP) to inhibit the Keap1‐Nrf2 interaction. The PLP platform technology provides stability in vivo, potent intracellular bioactivity, and multivalency leading to high avidity Keap1 binding. In vitro and in vivo assays to probe cellular activity and MI therapeutic utility are employed. These Keap1‐inhibiting PLPs (Keap1i‐PLPs) impart cytoprotection from oxidative stress via Nrf2 activation at sub‐nanomolar concentrations in primary cardiomyocytes. Single‐digit mg kg −1 , single‐dose, intravenous PLP administration significantly improves cardiac function in rats post‐MI through immunomodulatory, anti‐apoptotic, and angiogenic mechanisms. Thus Keap1i‐PLPs disrupt key intracellular protein–protein interactions following intravenous, systemic administration in vivo. These results have broad implications not only for MI but also for other oxidative stress‐driven diseases and conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2Kelch-Like ECH-Associated Protein 1Myocardial InfarctionPolymersAnimalsRatsOxidative StressHumansMyocytes, CardiacMaleRats, Sprague-Dawley

Stichwörter der Autor:innen

biomaterialdrug deliverymyocardial infarctionpolymers

Substanzen

NF-E2-Related Factor 2Kelch-Like ECH-Associated Protein 1Polymers

Autor:innen und Institutionen

  • Shu Chien-Gene Lay Department of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California San Diego, La Jolla, CA, 92037, USA.
  • Medical Scientist Training Program, Department of Biomedical Engineering, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
  • Program in Materials Science and Engineering, Sanford Consortium for Regenerative Medicine, University of California San Diego, La Jolla, CA, 92037, USA.
  • Department of Chemistry, International Institute for Nanotechnology, Simpson-Querrey Institute, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, 60208, USA.
  • Department of Chemistry, Department of Materials Science & Engineering, Department of Pharmacology, International Institute for Nanotechnology, Simpson-Querrey Institute, Chemistry of Life Processes Institute, Northwest…
  • Shu Chien-Gene Lay Department of Bioengineering, Program in Materials Science and Engineering, Sanford Consortium for Regenerative Medicine, Sanford Stem Cell Institute, University of California San Diego, La Jolla, CA,…

ORCID-Profile: Joshua M Mesfin, Kendal P Carrow, Madeline P Hopps, Assa Magassa, Karen L Christman, Nathan C Gianneschi

Förderung

  • NCI NIH HHS
  • Lurie Cancer Center
  • NIBIB NIH HHS
  • AHA post-doctoral fellowship
  • Basic Research Laboratory
  • NIH T32 Training
  • NHLBI NIH HHS
  • AHA pre-doctoral fellowship

Zitieren

APA

Mesfin, J. M., Carrow, K. P., Chen, A., Hopps, M. P., Holm, J. J., Lyons, Q. P., Nguyen, M. B., Hunter, J. D., Magassa, A., Wong, E. G., Reimold, K., Paleti, S. N., Gardner, E., Thompson, M. P., Luo, C. G., Zhang, X., Christman, K. L., & Gianneschi, N. C. (2025). Protein‐Like Polymers Targeting Keap1/Nrf2 as Therapeutics for Myocardial Infarction. Advanced Materials, 37(27). https://doi.org/10.1002/adma.202417885

Vancouver

Mesfin JM, Carrow KP, Chen A, Hopps MP, Holm JJ, Lyons QP, et al. Protein‐Like Polymers Targeting Keap1/Nrf2 as Therapeutics for Myocardial Infarction. Advanced Materials. 2025;37(27). doi:10.1002/adma.202417885

BibTeX
@article{Mesfin2025,
  author = {Mesfin, Joshua M and Carrow, Kendal P and Chen, Alexander and Hopps, Madeline P and Holm, JoJo J and Lyons, Quincy P and Nguyen, Michael B and Hunter, Jervaughn D and Magassa, Assa and Wong, Elyse G and Reimold, Kate and Paleti, Sriya N and Gardner, Emily and Thompson, Matthew P and Luo, Colin G and Zhang, Xiaoyu and Christman, Karen L and Gianneschi, Nathan C},
  title = {Protein‐Like Polymers Targeting Keap1/Nrf2 as Therapeutics for Myocardial Infarction},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {27},
  doi = {10.1002/adma.202417885}
}
Kostenlos starten →